-transparent.png){kind=logo}
A prospective study for histiocytosis X was designed to determine whether "good risk" patients, ie, those without evidence of dysfunction of liver, lung, or hemopoietic system, would respond to single agent therapy; in this case chlorambucil (CMB) used in a dose of 5 mgm/m2/day. If there was no response after an adequate trial period, treatment was initiated with four drugs using a combination of prednisone, vinblastine, cyclophosphamide and methotrexate. There were 26 evaluable patients, 57% of whom were less than two years of age at onset of therapy. There were three complete and four partial responses to CMB for a response rate of 26.9%. Sixteen patients received an adequate trial of four-drug therapy with three complete and two partial responses for a response rate of 33%. These responses were inferior to those previously reported for either single agents or combined therapy in histiocytosis X.
M E Lahey, and
R M Heyn, and
W A Newton, and
N Shore, and
W B Smith, and
S Leikin, and
D Hammond
February 1980,
The Journal of pediatrics,
M E Lahey, and
R M Heyn, and
W A Newton, and
N Shore, and
W B Smith, and
S Leikin, and
D Hammond
October 1984,
American journal of clinical oncology,
M E Lahey, and
R M Heyn, and
W A Newton, and
N Shore, and
W B Smith, and
S Leikin, and
D Hammond
November 1987,
Cancer treatment reports,
M E Lahey, and
R M Heyn, and
W A Newton, and
N Shore, and
W B Smith, and
S Leikin, and
D Hammond
February 1979,
Cancer,
M E Lahey, and
R M Heyn, and
W A Newton, and
N Shore, and
W B Smith, and
S Leikin, and
D Hammond
January 1988,
Medical and pediatric oncology,
M E Lahey, and
R M Heyn, and
W A Newton, and
N Shore, and
W B Smith, and
S Leikin, and
D Hammond
January 1979,
Medical and pediatric oncology,
M E Lahey, and
R M Heyn, and
W A Newton, and
N Shore, and
W B Smith, and
S Leikin, and
D Hammond
October 1988,
Human pathology,
M E Lahey, and
R M Heyn, and
W A Newton, and
N Shore, and
W B Smith, and
S Leikin, and
D Hammond
September 1989,
Cancer,
M E Lahey, and
R M Heyn, and
W A Newton, and
N Shore, and
W B Smith, and
S Leikin, and
D Hammond
November 1991,
Investigational new drugs,
M E Lahey, and
R M Heyn, and
W A Newton, and
N Shore, and
W B Smith, and
S Leikin, and
D Hammond
April 1992,
American journal of clinical oncology,
